

US EPA ARCHIVE DOCUMENT

1 EPA-HSRB-10-02

2

3 Paul Anastas, PhD

4 EPA Science Advisor

5 Office of the Science Advisor

6 1200 Pennsylvania Avenue, NW

7 Washington, DC 20460

8

9 Subject: October 27-28, 2010 EPA Human Studies Review Board Meeting Report

10

11 Dear Dr. Anastas,

12

13 The United States Environmental Protection Agency (EPA or Agency) requested that the
14 Human Studies Review Board (HSRB) provide scientific and ethics reviews of two new and one
15 revised protocols for studies involving intentional exposure of human subjects to pesticides: a
16 proposed Carroll-Loye Biological Research, Inc. (CLBR) insect repellent efficacy study (No
17 Mas-003); a proposed Agricultural Handler Exposure Task Force, LLC (AHETF) scenario
18 measuring dermal and inhalation exposure by pesticide applicators who use backpack sprayers or
19 hand gun sprayers in utility rights-of-way (AHE-400); and a revised AHETF water-soluble
20 packaging mixing and loading scenario and protocol (AHE-120) previously reviewed by the
21 HSRB in June 2009.

22

23 The Agency also requested that the HSRB review a completed study of dermal and
24 inhalation exposure of professional janitorial workers who clean floors with an antimicrobial
25 pesticide product using a mop and bucket, conducted by the Antimicrobial Exposure Assessment
26 Task Force II (AEATF II). This study (AEA-03) was conducted after publication of the EPA's
27 expanded final rule for protection of subjects in human research (40 CFR 26) on February 6,
28 2006 (71 Federal Register 24, 6137). The data will be posted to the Biocide Handlers Exposure
29 Database (BHED®), and used generically to estimate daily dermal and inhalation exposures of
30 those who clean floors with antimicrobial pesticides using a mop and pail.

31

32 The enclosed report provides the Board's response to EPA charge questions presented at
33 the October 27-28, 2010 meeting.

34

35 Assessment of Proposed Carroll-Loye Biological Research Study No Mas-003: Field Efficacy
36 Test of 16% Para-menthane-3,8-diol (PMD) and 2% Lemongrass Oil Based Repellent 'No Mas'
37 Against Mosquitoes.

38

39 Science

40

- 41 • The Board concluded that the protocol for the proposed field repellency study, if
42 modified in accordance with Agency and HSRB recommendations and conducted
43 accordingly, is likely to generate scientifically reliable data, useful for assessing the
44 efficacy of the tested material in repelling mosquitoes.

45

46 Ethics

- 47
- 48 • The Board concluded that the protocol submitted for review, if modified in accordance
49 with Agency and HSRB recommendations and conducted accordingly, is likely to meet
50 the applicable requirements of 40 CFR 26, subparts K and L.

51

52 Assessment of Proposed AHETF Scenario and Protocol AHE-400: Backpack and Handgun Ap-
53 plication of Liquid Sprays in Utility Rights-of-Way.

54

55 Science

- 56 • The Board concluded the proposed backpack and handgun application scenario, if revised
57 as suggested and performed as described, is likely to generate scientifically reliable data
58 that may be useful for assessing the exposure of workers who apply pesticides in utility
59 rights-of-way using backpack or handgun sprayers.

60

61

62 Ethics

- 63 • The Board concluded that the protocol submitted for review, if modified in accordance
64 with Agency and HSRB recommendations and conducted accordingly, is likely to meet
65 the applicable requirements of 40 CFR 26, subparts K and L.

66

67

68 Assessment of Revised AHETF Scenario and Protocol AHE-120: Water-Soluble Packaging Mix-
69 ing and Loading.

70

71 Science

- 72 • The Board concluded the submitted protocol, if revised as suggested and performed as
73 described, is likely to generate scientifically reliable data that may be useful for assessing
74 the exposure of workers who mix and load pesticides in water-soluble packaging.

75

76

77 Ethics

- 78 • The Board concluded that the protocol submitted for review, if modified in accordance
79 with Agency and HSRB recommendations and conducted accordingly, is likely to meet
80 the applicable requirements of 40 CFR 26, subparts K and L.

81

82

83 Assessment of Completed AEATF II Research Study AEA-03: A Study for Measurement of Po-
84 tential Dermal and Inhalation Exposure during Application of a Liquid Antimicrobial Pesticide
85 Product Using Bucket and Mop Equipment for Cleaning Indoor Surfaces (MRID 48210201,
86 MRID 48231201, MRID 48231901).

87

88 Science

- 89 • The Board concurred with the Agency's assessment that the research reported in the
90 completed AEA-03 study report and associated supplemental documents was conducted

92 in a manner that was reasonably faithful to the design and objectives of the protocol and
93 governing documents of AEATF-II.

- 94
- 95 • The Board concluded that the Agency has adequately, if not completely, considered the
96 limitations on these data that should be considered when using the data in estimating
97 exposure of those who apply antimicrobial floor-cleaning products with mop and bucket.
- 98

99 Ethics

- 100
- 101 • The Board concurred with the Agency's assessment that the study submitted for review
102 was conducted in substantial compliance with subparts K and L of 40 CFR 26.
 - 103
 - 104 • In response to a request from the study sponsor for guidance on how to provide
105 individual exposure data to participants once the study is complete, the Board elected to
106 establish a working group that could draft proposed guidance for the Agency and
107 sponsors, which would be reviewed by the full Board during a future HSRB meeting.
- 108

109

110 Sincerely,

111



112
113
114 Sean Philpott, PhD, MSBioethics
115 Chair
116 EPA Human Studies Review Board

NOTICE

117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133

This report has been written as part of the activities of the EPA Human Studies Review Board, a Federal advisory committee providing advice, information and recommendations on issues related to scientific and ethical aspects of human subjects research. This report has not been reviewed for approval by the Agency and, hence, the contents of this report do not necessarily represent the view and policies of the Environmental Protection Agency, nor of other agencies in the Executive Branch of the Federal government, nor does the mention of trade names or commercial products constitute a recommendation for use. You may obtain further information about the EPA Human Studies Review Board from its website at <http://www.epa.gov/osa/hsrb>. You may also contact the HSRB Designated Federal Officer, via e-mail at ord-osa-hsrb@epa.gov

In preparing this document, the Board carefully considered all information provided and presented by the Agency presenters, as well as information presented by public commenters. This document addresses the information provided and presented within the structure of the charge by the Agency.

US EPA ARCHIVE DOCUMENT

**US ENVIRONMENTAL PROTECTION AGENCY
HUMAN STUDIES REVIEW BOARD**

134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179

Chair

Sean Philpott, PhD, MSBioethics, Director for Research Ethics, The Bioethics Program of Union Graduate College and the Mount Sinai School of Medicine, Schenectady, NY

Vice Chair

Janice Chambers, PhD, DABT, Fellow ATS, William L. Giles Distinguished Professor, Director, Center for Environmental Health Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS

Members

George Fernandez, PhD, Professor of Applied Statistics, Director of the University of Nevada-Reno Center for Research Design and Analysis, University of Nevada-Reno, Reno, NV

Vanessa Northington Gamble, MD, PhD, University Professor of Medical Humanities, Professor of Health Policy and American Studies, The George Washington University, Washington, DC

Sidney Green, Jr., PhD, Fellow of the ATS, Professor, Department of Pharmacology, Howard University College of Medicine, Washington, DC

Dallas E. Johnson, PhD, Professor Emeritus, Department of Statistics, Kansas State University, Manhattan, KS

Michael D. Lebowitz, PhD, FCCP, Retired Professor of Public Health & Medicine, University of Arizona, Tucson, AZ

Jose E. Manautou, PhD, Associate Professor of Toxicology, Department of Pharmaceutical Science, University of Connecticut School of Pharmacy, Storrs, CT

Jerry A. Menikoff, MD, JD, Director, Office for Human Subjects Research, Office of the Secretary, Department of Health and Human Services, Rockville, MD

Rebecca Parkin, PhD, MPH, Professorial Lecturer (EOH) Human Risk Assessment, School of Public Health and Human Services, The George Washington University, Washington, DC

William Popendorf, PhD, MPH, Professor Emeritus, Department of Biology, Utah State University, Logan, UT

Virginia Ashby Sharpe, PhD, Medical Ethicist, National Center for Ethics in Health Care, Veterans Health Administration, Washington, DC

US EPA ARCHIVE DOCUMENT

DRAFT

180 Linda J. Young, PhD, Professor, Department of Statistics, Institute of Food and Agricultural
181 Sciences, University of Florida, Gainesville, FL

182

183 Human Studies Review Board Staff

184

185 Jim Downing, Executive Director, Human Studies Review Board Staff, Office of the Science
186 Advisor, United States Environmental Protection Agency, Washington, DC

187 **INTRODUCTION**
188

189 On October 27-28, 2010, the United States Environmental Protection Agency’s (EPA or
190 Agency) Human Studies Review Board (HSRB) met to address scientific and ethical issues
191 concerning two new protocols and one revised protocol for research involving human
192 participants: one new study measuring the efficacy of an insect repellent containing para-
193 menthane-3,8-diol (PMD) and lemongrass oil against mosquitoes under field conditions; one
194 new study measuring levels of exposure received by agricultural handlers when applying
195 commercially-available pesticides using backpack sprayers or hand gun sprayers in utility rights-
196 of-way, and a revised study measuring levels of exposure received by agricultural handlers when
197 mixing and loading pesticides using water-soluble packaging under various conditions. In
198 accordance with 40 CFR 26.1601, EPA sought HSRB review of these three proposed protocols.
199 Each of these protocols is discussed more fully below.
200

201 In addition, the Agency has data from one completed study measuring levels of exposure
202 received by janitorial workers when applying a commercially-available antimicrobial pesticide
203 using a mop and bucket. In accordance with 40 CFR 26.1602, EPA sought HSRB review of this
204 completed study. This completed study is discussed more fully below.
205

206 **REVIEW PROCESS**
207

208 On October 27-28, 2010, the Board conducted a public face-to-face meeting in Arlington,
209 Virginia. Advance notice of the meeting was published in the Federal Register as “Human
210 Studies Review Board; Notice of Public Meeting” (75 Federal Register 193, 61748).
211

212 Following welcoming remarks from Agency officials, the Board heard presentations from
213 EPA on the following topics: one new study protocol to measure the efficacy of an insect
214 repellent containing PMD and lemongrass oil against mosquitoes under field conditions; one new
215 study protocol for measuring levels of exposure received by agricultural handlers when applying
216 commercially available pesticides using backpack sprayers or hand gun sprayers in utility rights-
217 of-way, and a revised study protocol measuring levels of exposure received by agricultural
218 handlers when mixing and loading pesticides using water-soluble packaging under various
219 conditions. In addition, a completed study for the measurement of potential dermal and
220 inhalation exposure during application of a liquid antimicrobial pesticide product using a bucket
221 and mop was reviewed.
222

223 The Board also asked clarifying questions of several study sponsors and/or research
224 investigators, including:
225

- 226 Dr. Victor Cañez, Technical Chair, Agricultural Handler Exposure Task Force
- 227 Dr. Scott Carroll, Study Director, Carroll-Loye Biological Research
- 228 Mr. Shawn King, Director of Operations, Carroll-Loye Biological Research
- 229 Mr. Robert Roogow, Chief Operations Officer, Independent Institutional Review Board,
230 Inc.
- 231 Dr. Sami Selim, Study Director, Selim & Associates
232

233 Public oral comments were provided by:

234

235 Dr. Victor Cañez, Technical Chair, Agricultural Handler Exposure Task Force

236 Dr. Scott Carroll, Principal, Carroll-Loye Biological Research

237 Dr. Hasmukh Shah, Manager, AEATF

238

239 No written public comments were submitted.

240

241 For their deliberations, the Board considered the materials presented at the meeting, oral
242 comments, and Agency background documents (e.g., published literature, sponsor and
243 investigator research reports, study protocols, data evaluation records, and Agency science and
244 ethics reviews of proposed protocols and completed studies). A comprehensive list of
245 background documents is available online at <http://www.regulations.gov>.

246

247 **CHARGE TO THE BOARD AND BOARD RESPONSE**

248

249 **Assessment of Proposed Carroll-Loye Biological Research Study No Mas-003: Field** 250 **Efficacy Test of 16% Para-menthane-3,8-diol (PMD) and 2% Lemongrass Oil Based** 251 **Repellent ‘No Mas’ Against Mosquitoes.**

252

253 **Overview of the Study**

254

255 This protocol describes a study to test the repellent efficacy of a lotion formulation con-
256 taining 16% PMD and 2% lemongrass oil (‘No Mas’) against three species of mosquitoes in the
257 field. As submitted to the EPA, the proposed study consists of two interdependent analyses: 1) a
258 dosimetry study designed to determine the amount of lotion that typical users would typically
259 apply; and 2) an efficacy study designed to measure the effectiveness of the compound as a re-
260 pellent for those species of mosquitoes likely to be vectors for West Nile Virus (WNV) in the
261 United States.

262

263 Dosimetry will be determined by direct measurement of compound application. The effi-
264 cacy of the formulation as a mosquito repellent will be determined by measuring the ability of
265 the formulations to prevent mosquito landings under field conditions at test sites in California’s
266 Central Valley. The efficacy study endpoint will be the “Landing with Intent to Bite” (LIBe), and
267 the criterion for data to calculate complete protection time will be the first confirmed LIBe.

268

269 **Science**

270

271 **Charge to the Board**

272

273 If the proposed field repellency study protocol No Mas-003 is revised as suggested in
274 EPA’s review and if the research is performed as described, is the research likely to generate
275 scientifically reliable data, useful for assessing the efficacy of the tested material in repelling
276 mosquitoes?

277

278 **Board Response to the Charge**

279

280 HSRB Recommendation

281

282 The Board concurred with the Agency's assessment that the proposed field repellency
283 study protocol No Mas-003, if revised as suggested in EPA's review (Fuentes and Sherman 2010)
284 and performed as described, is likely to generate scientifically reliable data, useful for assessing
285 the efficacy of the tested material in repelling mosquitoes.

286

287 HSRB Detailed Recommendations and Rationale

288

289 Protocol No Mas-003 from Carroll-Loye Biological Research (Carroll 2010) will be
290 conducted using methods similar to those presented to and commented on by the Board in the
291 past. Apart from the new test material, the proposal is generally similar to previous Carroll-Loye
292 field studies reviewed by the Board.

293

294 The study protocol was relatively clear and addressed adequately a number of key
295 scientific issues, including: scientific justification, objectives, and data collection and
296 compilation methods. The Board concurred with the Agency's assessment that the proposed field
297 repellency study protocol No Mas-003 is likely to generate scientifically reliable data, useful for
298 assessing the efficacy of the tested material in repelling mosquitoes. In addition, the Board
299 recommended two minor changes to the protocol and associated study documents. First, the
300 protocol should be amended to remove erroneous reference to spray repellents (e.g. the first
301 sentence on page 79, under "Rationale"; Carroll 2010, 79). Second, the Board agreed with the
302 Agency that reference to sample size standards is now irrelevant in light of recently released
303 repellency testing guidelines. Rather than refer to a historical standard of 6 study participants, the
304 proposed sample size should be large enough to be likely to yield a definitive answer to the
305 research question and its size justified statistically in the protocol.

306

307 **Ethics**

308 **Charge to the Board**

309 If the proposed field repellency study protocol No Mas-003 is revised as suggested in
310 EPA's review and if the research is performed as described, is the research likely to meet the ap-
311 plicable requirements of 40 CFR part 26, subparts K and L?

312

313 **Board Response to the Charge**

314 HSRB Recommendation

315 The Board concluded that the protocol submitted for review, if modified in accordance
316 with EPA (Fuentes and Sherman 2010) and HSRB recommendations, is likely to meet the ap-
317 plicable requirements of 40 CFR 26, subparts K and L.

318 HSRB Detailed Recommendation and Rationale

319 The submitted documents assert that the study will be conducted in accordance with the
320 ethical and regulatory standards of 40 CFR 26, Subparts K and L, as well as the requirements the
321 US EPA's Good Laboratory Practice (GLP) Standards described at 40 CFR 160, and the Califor-
322 nia State EPA Department of Pesticide Regulation study monitoring (California Code of Regula-
323 tions Title 3, Section 6710) (Carroll 2010). Requirements of FIFRA §12(a)(2)(P) also apply. The
324 protocol was reviewed and approved by an independent human subjects review committee,
325 Independent Institutional Review Board (IIRB), Inc. of Plantation, FL prior to submission. IIRB,
326 Inc. is fully accredited by the Association for the Accreditation of Human Research Protection
327 Programs (AAHRPP). IIRB is also listed as an active Institutional Review Board (IRB) on the
328 Office of Human Research Protection (OHRP) website (Reg. #IORG0002954). Minutes of
329 IIRB, Inc. meetings (Carroll 2010) and a copy of IIRB, Inc. policies and procedures were pro-
330 vided to the Agency. These documents indicate that IIRB, Inc. reviewed this protocol pursuant to
331 the standards of the Common Rule (45 CFR Part 46, Subpart A).
332

333 1. Except as noted below, the Board concurred with the conclusions and factual observations of
334 the ethical strengths and weaknesses of the study, as detailed in the EPA's Ethics Review
335 (Fuentes and Sherman 2010). The proposed study is likely to meet the applicable ethical re-
336 quirements for research involving human subjects, in accordance with the following criteria:
337

338 a. Acceptable risk-benefit ratio. The risks as noted in the study protocol are fivefold: 1) al-
339 lergic reaction to test materials themselves; 2) exposure to biting arthropods; 3) possible
340 exposure to arthropod-borne diseases; 4) physical stress from the test conditions; and 5)
341 psychological stress and/or breach of confidentiality for pregnancy test results. These
342 risks are minimized appropriately and are justified by the potential societal benefits asso-
343 ciated with data on the efficacy of the active ingredients, PMD and lemongrass oil, as
344 mosquito repellents.
345

346 • Based on toxicological data currently available for PMD and lemongrass oil, cou-
347 pled with appropriate exclusion criteria, study participants are unlikely to be at risk
348 of adverse side effects with exposure.
349

350 • The study is designed to minimize the likelihood of mosquito bites, through the use
351 of: LIBes rather than actual confirmed bites as a study endpoint; bite removal and
352 joint observation; clear stopping rules; and limited periods of exposure to mosqui-
353 toes. Study participants will be trained in proper insect observation and handling
354 techniques.
355

356 • Mosquito bites, should they occur, are usually mild and easily treated with over-the-
357 counter steroidal creams. The study will also exclude participants who have a his-
358 tory of severe skin reactions to such bites.
359

360 • Possible exposure to vectors of arthropod-borne diseases is minimized through the
361 use of certified disease-free laboratory-reared insect populations, selection of field
362 sites in low virus areas, and limited skin exposure.
363

- 364
- 365
- 366
- 367
- 368
- 369
- 370
- 371
- 372
- 373
- The potential risks to participants from environmental stress are minimized by the provision of a climate controlled rest area, food, water and medical supplies, and by careful monitoring for signs of dehydration, heat stress and hypothermia. Appropriate stopping rules and medical management procedures are in place.
 - Minor and pregnant or lactating women are excluded from participation, with pregnancy either confirmed by over-the-counter pregnancy testing on the day of study or by opt-out. Only volunteers scored as non-pregnant will be allowed to participate. Information regarding pregnancy test results will be kept confidential.

374 b. Voluntary and informed consent of all participants

- 375
- 376
- 377
- 378
- 379
- 380
- 381
- 382
- 383
- 384
- 385
- There is the possibility that the participants in this study might represent particularly vulnerable populations, susceptible to coercion and undue influence. The study protocol, however, includes several mechanisms designed to minimize coercive recruitment and enrollment.
 - The informed consent materials, if changed as recommended by the HSRB below, will adequately inform the subjects of the risks, discomforts and benefits from participation, and of their right to withdraw.
 - Monetary compensation is not so high as to unduly influence participants.

386 c. Equitable selection of study participants

- 387
- 388
- 389
- 390
- 391
- 392
- 393
- The majority of research participants will be recruited from the University of California at Davis student population. Study participants are likely to represent the appropriate ethnic and racial diversity of individuals in and around the University, but the use of this convenience sample may limit the broad applicability of the study results to the general population. The investigators have noted this fact in the protocol (Carroll 2010).

394 2. The Board recommended that the study protocol be modified to address the concerns noted in

395 the EPA's Ethics Review (Fuentes and Sherman 2010). In addition, the Board also raised the

396 following concerns:

- 397
- 398
- 399
- 400
- 401
- 402
- 403
- 404
- 405
- 406
- 407
- 408
- The Board concurred with the Agency's recommendation that the protocol be revised to exclude as participants employees of the study sponsor. The Board added the recommendation that this exclusion also be extended to dependents of the study sponsor or sponsor employees.
 - The consent form and protocol should be modified as follows:
 - 1) Carroll-Loye should add "child/minor" to the list of exclusion criteria.
 - 2) The term "treatment" is used ambiguously throughout the protocol and informed consent form to describe both the application of the test materials and treatment for

409 research-related injuries. For example, on page 23 the protocol states that “applica-
410 tion of a test material is considered a treatment” (Carroll 2010, 23). Elsewhere,
411 however, the protocol states that “candidates are again encouraged to ask any ques-
412 tions they have about the study, which may include understanding ... treatment and
413 compensation for injury more fully” (Carroll 2010, 17, 238). This ambiguity should
414 be resolved with the use of a different term to describe the application of test mate-
415 rials.

- 416
- 417 3) On page 16, the protocol states that “...dosimetry subjects may be consented before
418 repellency subjects. Untreated control subjects for the repellency phase (field study)
419 are consented before the treated subjects for that phase...” (Carroll 2010, 16). The
420 verb “to consent” is an intransitive verb; from a grammatical point of view, some-
421 one cannot “be consented.” From an ethical perspective, this infelicitous use of the
422 verb also employs the passive voice, which is not best practice when the issue is to
423 affirm that researchers will be accountable for obtaining informed consent. It is
424 recommended that the protocol be modified to use alternate phrasing such as “Re-
425 searchers may obtain informed consent from dosimetry subjects before repellency
426 subjects ...”
- 427
- 428 4) Carroll-Loye should spell out the acronym “PMD” when it is first used in the proto-
429 col and consent form.
- 430
- 431 5) On page 2 of the consent form, the phrase “You have been offered an opportunity to
432 participate in this research study because ...” (Carroll 2010, 199, 209, 219) be
433 modified by Carroll-Loye to minimize the impression that participation in this in-
434 tentional exposure study is somehow a beneficial or favorable occasion. A neutral
435 alternative might be: “We are asking you to participate in this research study be-
436 cause...”
- 437
- 438 6) A description of the symptoms of heat stress and equine encephalitis should also be
439 included in the consent form. Currently, only the symptoms of West Nile Virus are
440 listed.
- 441

442 **Assessment of Proposed AHETF Scenario and Protocol AHE-400: Backpack and Handgun**
443 **Application of Liquid Sprays in Utility Rights-of-Way.**

444

445 **Overview of the Study**

446

447 This proposal presents an agricultural handler exposure scenario involving backpack and
448 handgun application of liquid pesticides along utility rights-of-way. The protocol calls for study
449 participants to apply (and potentially load) four surrogate pesticides (fosamine, glyphosate,
450 imazapyr and 2,4-D). A total of 21 participants (described in the protocol as “Monitoring Units”
451 [MUs]) will be observed for each scenario; three volunteers each from seven geographically
452 distinct growing regions will be enrolled using a purposive sampling method (with some
453 elements of random selection).

454

455 Dermal exposure will be measured by a whole body dosimeter (WBD) worn beneath the
456 subject's outer clothing. Hand wash and face/neck wipe samples will also be collected prior to,
457 during, and after completion of pesticide loading and mixing procedures. Airborne concentra-
458 tions of the surrogate will be monitored in the participant's breathing zone using an OSHA Ver-
459 satile Sampler (OVS) tube sample collector connected to a personal sampling pump. Additional
460 measures will also record environmental conditions at the time of monitoring, and observers will
461 make field notes, photographs and videos of participant activity throughout the monitoring event.
462

463 The results of sample analysis under the backpack and handgun application scenario will
464 be posted to the AHED® database, where they will be available to the EPA and other regulatory
465 agencies for statistical analysis. The proposed documentation will report a confidence-interval-
466 based approach to determine the relative accuracy for the arithmetic mean and 95th percentile of
467 unit exposures. The Agency proposes to use these data to estimate daily dermal and inhalation
468 exposures of agricultural handlers who are applying pesticides using backpack and/or handgun
469 applicators under a variety of scenarios.
470

471 Science

472 Charge to the Board

473 If the proposed AHETF Right-of-Way application scenario and field study proposal
474 AHE400 is revised as suggested in EPA's review and if the research is performed as described, is
475 the research likely to generate scientifically reliable data, useful for assessing the exposure of
476 workers who apply pesticides in utility rights-of-way using backpack or handgun sprayers?
477
478
479

480 Board Response to the Charge

481 HSRB Recommendation

482 The Board concurred with the Agency's assessment that the proposed AHETF Right-of-
483 Way application scenario and field study proposal AHE400, if revised as suggested in EPA's
484 review (Evans and Sherman 2010a) and performed as described, is likely to generate
485 scientifically reliable data useful for assessing the exposure of workers who apply pesticides in
486 utility rights-of-way using backpack or handgun sprayers.
487
488
489

490 HSRB Detailed Recommendations and Rationale

491 Given the lack of existing reliable and sound data in this area, the Board concurred with
492 the Agency's assessment (Evans and Sherman 2010a) that this protocol will likely generate data
493 that may be useful for assessing the exposure of handlers who apply pesticides using backpack or
494 handgun sprayers.
495
496

497 The study, if conducted as described, will provide newer exposure information on dermal
498 and inhalation exposures of pesticide handlers using backpack sprayers and handgun sprayers
499 treating utility rights-of-way in appropriate and distinct geographic locations; some study par-
500 ticipants will be exposed during loading backpacks or tanks as well. The Board agreed with the

501 Agency's assessment that the protocol adequately addresses a number of scientific questions, in-
502 cluding having clear scientific objectives, a reasonable experimental design for achieving these
503 objectives: appropriate quantification of test materials, adequate procedures for collecting, com-
504 piling and summarizing test results, appropriate justification for selection of test substances,
505 sample size, and study site selection, and acceptable QA/QC procedures.
506

507 However, the Board noted a few weaknesses in the proposed study design. In particular,
508 the variability in individual dermal and inhalation exposure levels may be extremely high be-
509 cause of the diversity of terrains and locations selected for the study and the opportunity for large
510 (but potentially categorical) personal differences in application practices. The proposal to impose
511 a minimum exposure duration of at least 4 hours will also create opportunities for the applica-
512 tor's exposures to be influenced by variables that by their nature are likely to be unrelated to the
513 amount of active ingredient handled (AaiH). Should this diversity yield high variability in the
514 data sets, then the proportionality of exposure with AaiH may not be apparent. If the 4-hour
515 minimum is not removed, the Task Force may want to ensure that field notes are adequate to re-
516 port time-on-task as a fraction of the total monitored time for use in later data analysis and usage
517 within AHED. The rationale for having and using this "fraction" is discussed more fully in the
518 Board's discussion of protocol AHE120 below. Even if the proportionality hypothesis is not sup-
519 ported by the resultant data sets, these data are likely to still be useful and relevant to assessing
520 the levels of exposure to workers applying pesticides to utility rights-of-way.
521

522 **Ethics**

523 **Charge to the Board**

524 If the proposed AHETF Right-of-Way application scenario and field study proposal
525 AHE400 is revised as suggested in EPA's review and if the research is performed as described, is
526 the research likely to meet the applicable requirements of 40 CFR part 26, subparts K and L?
527

528 **Board Response to the Charge**

529 HSRB Recommendation

530 The Board concluded that the protocol submitted for review, if modified in accordance
531 with EPA (Evans and Sherman 2010a) and HSRB recommendations, is likely to meet the ap-
532 plicable requirements of 40 CFR 26, subparts K and L.

533 HSRB Detailed Recommendation and Rationale

534 The submitted documents assert that the revised study will be conducted in accordance
535 with the ethical and regulatory standards of 40 CFR 26, Subparts K and L, as well as the re-
536 quirements the US EPA's GLP Standards described at 40 CFR 160 (AHETF 2010a; Collier
537 2010a). FIFRA §12(a)(2)(P) also applies. The protocol was reviewed and approved by an inde-
538 pendent human subjects review committee, IIRB, Inc. of Plantation, FL prior to submission.
539 Minutes of IIRB, Inc. meetings and a copy of IIRB, Inc. policies and procedures were provided.
540 This IRB is fully accredited by AAHRPP and listed by OHRP (see details above).
541

542 1. Except as noted below, the Board concurred with the conclusions and factual observations of
543 the ethical strengths and weaknesses of the study, as detailed in the EPA's Ethics Review
544 (Evans and Sherman 2010a). The proposed study is likely to meet the applicable ethical re-
545 quirements for research involving human subjects, in accordance with the following criteria:
546

547 a. Acceptable risk-benefit ratio. Risks as noted in the study protocol are four-fold: 1) heat-
548 related illness; 2) injury associated with scripted field activities; 3) allergic reaction to
549 surfactants using for hand washing; and 4) psychological stress and/or breach of confi-
550 dentiality for pregnancy test results. These risks are minimized appropriately and are jus-
551 tified by the potential societal benefits, particularly data for new exposure assessments
552 for occupational risks associated with spraying pesticides to rights-of-way using back-
553 pack and handgun sprayers.

- 554 • Only experienced pesticide handlers, with specific experience with the type of ap-
555 plication equipment to be used, and who consider themselves to be in good health,
556 will be enrolled.
- 557 • Risk of heat-related illness is minimized appropriately. Heat index will be moni-
558 tored with an associated stopping rule. A medical professional will be on site to ob-
559 serve the workers and provide urgent care. Nearby medical facilities have been
560 identified in case of emergency, and transportation to medical treatment will be
561 provided, if needed.
- 562 • Subjects will be reminded about safe chemical handling practices and procedures,
563 wearing appropriate personal protective equipment (PPE), and will be monitored for
564 any accidental or unintended product exposure.
- 565 • Minors and pregnant or lactating women are excluded from participation, with
566 pregnancy either confirmed by over-the-counter pregnancy testing on the day of
567 study or by opt-out. The potential stigma resulting from study exclusion due to
568 pregnancy is appropriately minimized.

569 The Board disagreed with the AHETF conclusion, however, that “the risk of toxicity from
570 pesticide handling [is not] strictly due to study participation [and therefore], the risk of
571 surrogate toxicity will not be listed in consent forms or this protocol” (Collier 2010a,
572 309). This study is subject to 40 CFR 26 subparts K and L precisely because it is consid-
573 ered to be a study in which the subjects are “intentionally exposed,” for research pur-
574 poses, to pesticides. Given its scripted nature, the AHETF protocol influences the behav-
575 ior of workers and their employers in a number of ways. That a particular agricultural
576 worker will be applying a particular pesticide on a particular day is due, to a large extent,
577 to the fact that the study is being conducted. Accordingly, the risk from exposure to the
578 pesticides being applied should clearly be categorized as a risk of study participation.

579 The Board does agree, however, that the risk from exposure to those pesticides is a rea-
580 sonable one, and that it has been appropriately minimized. The products being used in
581
582
583
584
585
586

587 this study are ones already registered by EPA for vegetation control in rights-of-way, and
588 will be applied in accordance with label requirements.

589
590

b. Voluntary and informed consent of all participants

591 • There is the possibility that the participants in this study might represent particularly
592 vulnerable populations, susceptible to coercion and undue influence. The study proto-
593 col, however, includes several mechanisms designed to minimize coercive recruitment
594 and enrollment.

595
596 • The informed consent materials, if changed as recommended by the HSRB below, will
597 adequately inform the subjects of the risks, discomforts and benefits from participation,
598 and of their right to withdraw.

599

600 • Monetary compensation is not so high as to unduly influence participants.

601

602 • Spanish translations of the informed consent documents, informational packets, and re-
603 cruitment flyers were provided. Researchers will be working with local Spanish-
604 speaking community members to ensure that the appropriate regional dialect of Spanish
605 is used (AHETF 2010b).

606

607 c. Equitable selection of study participants

608

609 • The study is designed to recruit an appropriately diverse population of participants who
610 represent skilled workers in the study locations.

611

612 • The study will first involve identifying and contacting the employers involved in right-
613 of-way application of pesticides. Only employees of these employers are eligible to be
614 recruited. The recruitment process has been carefully designed to assure that employees
615 will not be coerced into participating: recruitment will take place using brochures and
616 meetings with employees at which the employer and supervisors will not be present.

617

618 2. The Board recommended that the study protocol be modified to address the concerns noted in
619 the EPA's Ethics Review (Evans and Sherman 2010a). In addition, the Board also raised the
620 following concerns:

621

622 • As noted above, the Board concluded that the risk of toxicity from pesticide handling is in-
623 deed a risk of participating in the study, and accordingly it should be described as such, and
624 discussed appropriately, in the consent form.

625

626 • The consent form should explain that the pregnancy test will be provided by the research-
627 ers, and explain when it will take place.

628

629 • There appears to be a discrepancy between the exclusion criteria stated in the EPA review
630 (Evans and Sherman 2010a, 36), which refer to training in handling pesticides, and the
631 AHETF-provided consent form (AHETF 2010a, 267), which notes that the subject might

632 need only to confirm that “you are not required to take this training.” This discrepancy
633 should be clarified.

- 634
- 635 • Study participants will undergo hand washes prior to eating anything, which will reduce
636 their risk of accidental ingestion of the surrogate compounds. As many of the adults in the
637 US still smoke, however, hand washes should also occur before any smoking break to fur-
638 ther reduce participant’s risk of accidental pesticide ingestion.
- 639

640 **Assessment of Completed AEATF II Research Study AEA-03: A Study for Measurement of**
641 **Potential Dermal and Inhalation Exposure during Application of a Liquid Antimicrobial**
642 **Pesticide Product Using Bucket and Mop Equipment for Cleaning Indoor Surfaces (MRID**
643 **48210201, MRID 48231201, MRID 48231901).**

644

645 **Overview of the Study**

646

647 The objective of this study was to measure individual exposures to a surrogate antimicro-
648 bicidal pesticide (didecyl dimethyl ammonium chloride; DDAC) while mopping floors and emp-
649 tying mop buckets. Eighteen volunteers participated in the study, mopping floors in one of three
650 building types (an office building, a Rite Aid pharmacy building, or a retired teacher’s memorial
651 building in Fresno, CA) for one of six pre-determined mopping times (30-40, 40-50, 50-60, 60-
652 70, 70-80 and 80-90 minutes total mopping time, respectively).

653

654 Dermal and inhalation exposure monitoring was conducted while study participants
655 mopped floors and emptied the mop buckets; all participants wore long-sleeved shirts, long
656 pants, shoes, socks, and no gloves. Dermal exposure was measured by inner and outer body do-
657 simeters. Airborne concentrations of the surrogate compound were monitored in the participant’s
658 breathing zone using an OSHA Versatile Sampler (OVS) tube sample collector connected to a
659 personal sampling pump. Environmental conditions were also recorded at the time of monitoring,
660 and observers made notes, photographs and videos of participant activity throughout the mop-
661 ping period.

662

663 These exposure data will be used to populate a database representing inhalation and der-
664 mal exposure during a number of antimicrobial handler scenarios. A scenario is defined as a pes-
665 ticide handling task based on activity (e.g., application) and equipment type (e.g., mop & bucket,
666 ready-to-use wipes, pressure treatment of wood facilities, painting). These data will be used by
667 the Agency to estimate dermal and inhalation exposures of antimicrobial handlers who are apply-
668 ing pesticides using a mop and bucket under a variety of scenarios.

669

670 **Science**

671

672 **Charges to the Board**

673

- 674 1) Was the research reported in the Antimicrobial Exposure Assessment Task Force II (AEATF–
675 II) completed study report AEA-03 and associated supplemental reports faithful to the design
676 and objectives of the protocol and governing documents of AEATF-II?
- 677

- 678 2) Has the Agency adequately characterized, from a scientific perspective, the limitations on
679 these data that should be considered when using the data in estimating exposure of those who
680 apply antimicrobial floor-cleaning products with mop and bucket?
681

682 **Board Response to the Charge**

683
684 HSRB Recommendation
685

686 The Board concurred with the Agency's assessment (Leighton 2010) that the research
687 reported in the completed AEA-03 study report and associated supplemental documents (Selim
688 and Taylor 2010a, 2010b, 2010c) was conducted in a manner that was reasonably faithful to the
689 design and objectives of the protocol and governing documents of AEATF-II. The Board also
690 concluded that the Agency has adequately, if not completely, considered the limitations on these
691 data that should be considered when using the data in estimating exposure of those who apply
692 antimicrobial floor-cleaning products with mop and bucket.
693

694 HSRB Detailed Recommendations and Rationale
695

696 The study was conducted in a manner that was reasonably faithful to the design of the
697 protocol and governing documents. The study report (Selim and Taylor 2010a) contains sections
698 that adequately describe the test substance, recruitment procedures, field procedures, sample
699 collection and handling, sample analysis, and data analysis. Previous Board recommendations
700 (EPA HSRB 2008) for the use of a double layer of socks and provision of more detail about staff
701 activities during the observation period were adopted. Appropriate rationale for changes in key
702 elements of the study design, including justification for the purposive sampling of monitoring
703 events (MEs) and the sample size of 18, was also provided. Finally, assuming that only one
704 participant was present in the cluster when an ME was conducted, it also appears that no
705 participant observed another participant's activities during the study, as previously
706 recommended. However, some of the issues raised by the Board in its initial review of the mop
707 and bucket scenario (EPA HSRB 2008) were not addressed, including: the bases for the 90-
708 minute maximum mopping period choice, the possibility (or not) of "carry-over effects" between
709 MEs, and the interaction between aerosolized particles, heating, ventilation and air conditioning
710 (HVAC) systems, and inhalation exposure estimates. Although the importance of measuring the
711 impact of HVAC systems on inhalation exposures was mentioned in the protocol (Selim and
712 Taylor 2010a, 28), it was not given appropriate attention nor were HVAC operations consistently
713 documented during the conduct of the study. While this lack of information places potentially
714 important limitations on how the inhalation data should be interpreted, in the professional
715 opinion of at least one Board member the impact of differences among the test sites are likely to
716 be within a factor of about two and thus not substantively change the overall mean exposure
717 levels. The study was also conducted in a manner that was reasonably faithful to the objectives
718 of the protocol and governing documents. As stated in the final report, the study was conducted
719 primarily to "determine potential dermal and inhalation exposures to professional janitorial
720 workers when mopping indoor surfaces with a liquid antimicrobial pesticide product containing
721 didecyl dimethyl ammonium chloride (DDAC)" (Selim and Taylor 2010a, 28). Dermal exposures
722 were reported, with estimates based on total collected residue from all matrices (face and hand
723 wipes, socks, and all parts of the inner dosimeter). Dermal exposures were expressed as

724 micrograms of active ingredient (AI) handled per subject and as milligrams of AI per
725 subject/pound of AI applied. Inhalation exposure was also presented as units of concentration.
726 However, sufficient data is available (*i.e.*, the duration of each exposure) to express those results
727 in the same units as dermal exposures if an average respiratory minute volume for the applicators
728 is also applied to the calculation.
729

730 The overall study objective was listed differently in the Agency's scientific review than in
731 the protocol, stating it as: "the study objective is to monitor inhalation and dermal exposures to
732 be used as inputs in exposure algorithms to predict future exposures to persons mopping floors."
733 (Leighton 2010, 5). The Agency added two sub-objectives not found in the protocol: "to be 95%
734 confident that key statistics of normalized dermal exposure are accurate within 3-fold" and "to
735 evaluate the presumption of proportionality between exposure and amount of active ingredient
736 handled," respectively. The Agency provided a thorough assessment of their first sub-objective
737 supporting the sample size and analyses used to achieve the 3-fold accuracy goal. However,
738 although the presumption of proportionality was demonstrated for dermal exposure and the
739 amount of AI handled, the rationale supporting the presumption of proportionality for inhalation
740 exposure needs to be recalculated but based on current data may not be as clear and consistent as
741 for the dermal exposure.
742

743 The Agency's scientific review (Leighton 2010) discussed the limitations of the dermal
744 and inhalation exposure data. The Agency also presented alternative models for estimating
745 dermal and inhalation exposures, evaluated the impacts of non-detects and of assigning low
746 limits of quantification (LOQs) at 3 different values (0, 1/2 and full LOQ). The Agency concluded
747 that dermal exposures and pounds of active ingredient are related in a proportional manner, while
748 accounting for sampling efficiency and normalizing the data in terms of milligrams/pounds of
749 active ingredient applied. The Agency also discussed the dermal exposure estimates in
750 relationship to its sub-objectives of the study (accuracy within 3-fold and proportionality). Their
751 assessment acknowledged that some estimates included a high level of uncertainty and some
752 bias. The Board concluded that the Agency adequately, if not completely, considered limitations
753 in its interpretation and subsequent estimates of dermal exposure data. One Board member
754 observed, however, that the Agency's reliance on hand wash data may have over-corrected face
755 and neck residue estimates. Another Board member questioned whether the model actually
756 supports the conclusion of proportionality for some of the dermal configurations.
757

758 With respect to limitations of the inhalation exposure data due to study deviations, some
759 (but not all) of the limitations that need to be considered when estimating inhalation exposure
760 were discussed. In its initial 2008 review (EPA HSRB 2008), the Board noted several factors that
761 could influence these estimates, including: ventilation, room temperature, total area mopped,
762 duration of mopping, and volume of the enclosed space and respiration rate of the study
763 participants. Although the final study report provides some of these data for the facilities in
764 which mopping activities were conducted (Selim and Taylor 2010a, 105-7), neither ventilation
765 data nor a discussion of these factors were provided, thus limiting the Board's and Agency's
766 ability to interpret fully the reported environmental data. Furthermore, the rationale for the
767 Agency's conclusion that air changes per hour was not a significant factor influencing inhalation
768 exposure estimates, based on the low vapor pressure of DDAC and the LOQs observed, does not
769 recognize fully how HVAC parameters could have affected reported air concentrations from

770 mopping activities. The Agency also failed to consider whether the limited areas available for
771 mopping in Clusters 1 and 3 could have compromised the study design or affected inhalation
772 exposure estimates. Similarly, although surface areas of the floors mopped were noted, the
773 ceiling heights were not reported. The Agency's review also fails to consider the impact that
774 ceiling height and room volume may have had on the reported air concentration data. The
775 respiration rates of study participants were not discussed by the Task Force researchers or the
776 Agency; ignoring this factor could introduce important uncertainties into exposure estimates.
777 Finally, the Board's previous recommendation to consider particle size (e.g., whether DDAC is
778 aerosolized) and its potential impact on inhalation exposures were not addressed by the Agency.
779 Although not discussed in detail by the Board at the October 2010 meeting, several of these
780 factors are discussed in Appendix 1 below (written as a separate report by HSRB member Dr.
781 William Popendorf).

782
783 **Ethics**

784 **Charge to the Board**

785 Does available information support a determination that the study was conducted in sub-
786 stantial compliance with subparts K and L of 40 CFR Part 26?

787
788 **Board Response to the Charge**

789 HSRB Recommendation

790
791 The Board concurred with the Agency's assessment (Carley 2010) that the study was
792 conducted in substantial compliance with subparts K and L 40 CFR 26.

793
794 HSRB Detailed Recommendation and Rationale

795
796 The documents provided by Golden Pacific Laboratories, LLC, under Project No. AEA-
797 03, state that the study was conducted in compliance with the requirements of 40 CFR 26
798 subparts K, L and M; FIFRA § 12(a)(2)(P); and the California Code of Regulations Title 3,
799 Section 6710 (Selim and Taylor, 2010a, 2010b, 2010c). The protocol was reviewed and approved
800 by an independent human subjects review committee, IIRB, Inc. of Plantation, FL prior to
801 submission. Minutes of IIRB, Inc. meetings and a copy of IIRB, Inc. policies and procedures
802 were provided. This IRB is fully accredited by AAHRPP and listed by OHRP (see details above).

- 803
804 1. The Board concurred with the conclusions and factual observations relating to the study, as
805 detailed in the EPA's Ethics Review (Carley 2010) and summarized briefly below.
806
807 a. Prior HSRB and Agency Review. Because this study was initiated after 7 April 2006,
808 prior submission of the protocol and supporting materials to EPA was required by 40
809 CFR §26.1125. The requirements of 40 CFR §26.1125 for prior submission of the
810 protocol to EPA and of §26.1601 for HSRB review of the protocol were satisfied. The
811 scenario design and study were approved by IIRB, Inc. and submitted to the EPA in
812 February 2008. The HSRB discussed the protocol at its April 2008 meeting, concurring
813 with the Agency's assessment that the proposed mop and wipe scenario, if revised as

814 suggested by the Agency and the HSRB, would meet the applicable requirements of 40
815 CFR part 26, subparts K and L.

816

817 b. Responsiveness to HSRB and Agency Recommendations.

818

819 The Agency's initial ethics review noted two deficiencies to be corrected before the study
820 was initiated. The first focused on measures to improve the informed consent process for
821 Spanish-speaking candidates. The Agency called for the candidate interviews for Spanish
822 speakers to be conducted by a member of the research team fluent in Spanish, rather than
823 an independent translator. The second deficiency focused on references in the informed
824 consent forms to "normal business hours". The Agency asked that the researchers revise
825 the consent form to show hours for calling in local (Pacific) time.

826

827 In the revisions submitted to IIRB, Inc. in February 2009, the researchers addressed these
828 ethical concerns. Because the study was conducted in California, the approval of the
829 California Department of Pesticide Regulation (CDPR) was also required. CDPR granted
830 final approval of the amended protocol and supporting documents in April 2009.

831

832 b. Responsiveness to HSRB and Agency Reviews. The Agency's and HSRB's comments
833 were satisfactorily addressed in the revisions approved by the IIRB in March 2009 (Selim
834 and Taylor 2010a).

835

836 At its April 2008 meeting, the HSRB made several specific recommendations for
837 refinements of the study. As noted in Amendment 4 of the Agency's ethics review
838 (Carley 2010), the investigators addressed fully most of these recommendations,
839 addressed partially some of these recommendations, and did not address two of these
840 recommendations. The Board agreed with the Agency conclusion, however, that the
841 investigators' failure to address all of the recommendations did not violate applicable
842 ethical standards for the protection of human participants of research.

843

844 c. Substantial Compliance with Reporting Requirements (40 CFR §26 subpart M).

845

846 The study sponsor initially did not provide adequate documentation to demonstrate that
847 they had satisfied the requirements of §26.1303. The initial report (Selim and Taylor,
848 2010a) contained several reporting deficiencies, including: inadequate documentation of
849 interaction between the investigators and the overseeing IRB, incomplete study
850 chronology, and a lack of tracked consent forms showing how they were revised to
851 address Agency and HSRB concerns. These deficiencies were corrected by the
852 submission of supplemental documents (Selim and Taylor, 2010b, 2010c).

853

854 IRB minutes documenting discussion and review of these revised documents were not
855 provided for review. All IIRB, Inc. reviews subsequent to the HSRB's April 2008
856 meeting were conducted using an expedited procedure and did not require a full meeting
857 of the IRB. Neither the IRB roster nor the operational procedures were submitted as part
858 of the study documents.

859

860 The HSRB agreed with the Agency that these deficiencies in the conduct and the
861 documentation of the research did not compromise the ethical conduct of the study, and
862 concluded that the requirements of 40 CFR §26.1303 were satisfactorily addressed. The
863 HSRB did recommend, however, that the Agency require the submission of reports for all
864 research that undergoes expedited IRB review in the future.
865

866 2. The Board concluded that this study, as conducted, met all applicable ethical requirements for
867 research involving human participants, in accordance with the following criteria that had
868 been stated in the Board's prior review of this protocol (EPA HSRB 2008).
869

870 a. Acceptable risk-benefit ratio. The risks to study participants were minimized
871 appropriately and were justified by the potential societal benefits, particularly data on the
872 dermal and inhalation exposure of professional janitorial workers to antimicrobial
873 pesticides as they mopped indoor floors and disposed of spent mop water. These data
874 could be used to develop mechanisms to protect future users of these antimicrobial
875 pesticides.
876

- 877 • Minors and pregnant or lactating women were excluded from participation, with
878 pregnancy confirmed by over-the-counter pregnancy testing on the day of study or by
879 opt-out. The potential of stigma resulting from study exclusion was also appropriately
880 minimized.
881
- 882 • Clear stopping rules and medical management procedures were in place, and no adverse
883 events or other incidents of concern related to product exposure were reported.
884
- 885 • The study was designed to minimize the risks of exposure to the test compounds.
886

887 b. Voluntary and informed consent of all participants
888

- 889 • The study protocol included several mechanisms designed to minimize coercive
890 recruitment and enrollment.
891
- 892 • Monetary compensation was not so high as to unduly influence participation.
893

894 3. Three minor protocol deviations were reported. These included: 1) most study participants
895 declining to take rest breaks or taking less than the 10 minutes provided for in the protocol;
896 2) full facial photographs taken of participants at one monitoring site; and 3) enrollment of
897 participants who self-reported that their health was only "fair," despite the requirement that
898 all participants be in "good health" (Selim and Taylor, 2010b, 31). The Board concluded,
899 however, that these minor deviations did not affect the integrity of the research or the safety
900 of participants. The Board did recommend, however, that sponsors clarify the criteria used to
901 establish participants' health status prior to study enrollment.
902

903 **Assessment of Revised AHETF Scenario and Protocol AHE-120: Water-Soluble Packaging**
904 **Mixing and Loading.**

905
906 **Overview of the Study**
907

908 This revised proposal presents an agricultural handler exposure scenario involving
909 mixing/loading of pesticides enclosed in water-soluble packets (WSP). The original protocol,
910 which was favorably reviewed by the Board at its June 2009 meeting (EPA HSRB 2009), called
911 for study participants to mix and load one of two WSP-enclosed surrogate pesticides (acephate
912 and carbaryl) into a variety of tanks containing water in a variety of agricultural spraying
913 operations. Carbaryl in water-soluble packaging is no longer being produced by pesticide
914 manufacturers; however, the AHETF proposed substituting three additional surrogate compounds
915 for carbaryl: dithiopyr, imidacloprid, and thiophanate-methyl. Because of use patterns of these
916 surrogate compounds, the AHETF also identified additional study sites. The previously reviewed
917 study was to be conducted at three cool dry sites in Michigan, New York, and Washington State,
918 one hot humid site in Louisiana, and one hot dry site in California. The revised protocol will also
919 be conducted at five sites, including two cool dry sites in New York and North Dakota, two hot
920 humid sites in Florida and Louisiana, and one hot dry site in California.

921
922 A total of 25 participants (described in the protocol as “Monitoring Units” [MUs]) will be
923 observed; five volunteers each from five different growing regions will be enrolled using a
924 purposive sampling method. Dermal exposure will be measured by a whole body dosimeter
925 (WBD) worn beneath the subject’s outer clothing. Hand wash and face/neck wipe samples will
926 also be collected prior to, during, and after completion of pesticide loading and mixing
927 procedures. Airborne concentrations of the surrogate will be monitored in the participant’s
928 breathing zone using an OSHA Versatile Sampler (OVS) tube sample collector connected to a
929 personal sampling pump. Additional measures will also record environmental conditions at the
930 time of monitoring, and observers will make field notes, photographs and videos of participant
931 activity throughout the monitoring event.

932
933 The results of sample analysis under the mixing/loading of water-soluble packets
934 scenario, and will be posted to the AHED® database, where they will be available to the EPA
935 and other regulatory agencies for statistical analysis. The Agency proposes to use these data to
936 estimate daily dermal and inhalation exposures of agricultural handlers who are mixing/loading
937 pesticides in water-soluble packets under a variety of mixing and loading scenarios.

938
939 **Science**

940
941 **Charge to the Board**
942

943 If the revised AHETF scenario and field study proposal AHE120 is revised as suggested
944 in EPA’s review and if the research is performed as described, is the research likely to generate
945 scientifically reliable data, useful for assessing the exposure of handlers who mix and load pesti-
946 cides in water-soluble packaging?
947

948 **Board Response to the Charge**

949

950 HSRB Recommendation

951

952 The Board concurred with the Agency's assessment (Evans and Sherman 2010b) that this
953 protocol will generate data that are scientifically valid and that may be useful for assessing the
954 exposure of handlers who mix and load soluble or wettable powder pesticides in water-soluble
955 packaging. The Board cautioned, however, that these data might not be useful for creating
956 distributions of worker exposure that are scientifically accurate or that are precise.

957

958 HSRB Detailed Recommendations and Rationale

959

960 The protocol is largely the same as when it was first reviewed by the HSRB in June 2009
961 (EPA HSRB 2009). The major changes are that one of the surrogate active ingredients (carbaryl)
962 was deleted and three other active ingredients (dithiopyr, imidacloprid, and thiophanate-methyl)
963 were added. This change necessitated revising the geographical regions in which the study could
964 be conducted and a slight lowering of each of the five strata in the amounts of active ingredient
965 handled.

966

967 Each of these changes seems justified. Assuming that the AHETF can provide adequate
968 evidence of the validity of the analytical methods for each of the new compounds, the revised
969 study protocol still allows a good probability of the study successfully obtaining its primary and
970 secondary objectives (i.e., "that selected lognormal-based estimates of normalized dermal expo-
971 sure distribution be accurate to within 3-fold, at least 95% of the time," and the ability to distin-
972 guish "a proportional from an independent relationship between exposure and AaiH," respec-
973 tively (Evans and Sherman 2010b, 28-9).

974

975 However, the Board pointed out that many of the same concerns it raised in June 2009
976 remain for the revised protocol. Of particular note is the conflict between the non-random, pur-
977 posive study design and the statistical methods proposed to analyze the exposure data. Moreover,
978 the protocol does not control for ecological, engineering, and statistical factors that may obscure
979 a linear relationship between AaiH and worker exposure. Previously the Board said that "there is
980 no statistical theory that can be applied to non-random samples of this type. Thus, the statistical
981 analyses proposed, including mixed model approaches, are not valid" (EPA HSRB 2009, 34). In
982 contrast to the prior version, this protocol indicates that AHETF will not statistically analyze the
983 monitoring data; that begs the question as to what statistical methods are appropriate to use on
984 these data.

985

986 The Board also raised one new concern regarding the potentially adverse impact of the
987 protocol's call for an exposure duration of at least 4 hours for all of the MUs. This constraint
988 seems unnecessary and may introduce unintended and undesired variability into the results. The
989 Board noted that scripting activities to include more time than would otherwise be required to
990 apply the amount of active ingredient in the designated stratum is likely to change the applica-
991 tor's exposures by introducing variables that by their nature are unrelated to the AaiH. In par-
992 ticular, other tasks within those hours are likely to result in the transfer of active ingredient either
993 to or from other surfaces from or onto the subject. For this study, the fraction of the total moni-

994 tored time that is time on-task is likely to be highly variable, probably among strata (particularly
995 if the artificial constraint on the minimum time monitored affects the low AaiH preferentially)
996 and potentially even within strata. While omitting this time constraint would avoid these random
997 variables, the Board recommended that all field notes for this study report the time on-task as a
998 fraction of the total monitored time, and that the total monitored time and the fraction of the total
999 time on-task be tabulated for this study. This fraction can be used later by the Agency, sponsors
1000 and AHED users to reliably extrapolate from the time-weighted average concentrations or rates
1001 of exposure measured by the existing protocols to task-specific concentrations or rates of dermal
1002 and inhalation exposure per AaiH.

1003 **Ethics**

1004 **Charge to the Board**

1005
1006 If the revised AHETF scenario and field study proposal AHE120 is revised as suggested
1007 in EPA's review and if the research is performed as described, is the research likely to meet the
1008 applicable requirements of 40 CFR part 26, subparts K and L?

1009 **Board Response to the Charge**

1010 HSRB Recommendation

1011
1012 The Board concluded that the protocol submitted for review, if modified in accordance
1013 with EPA (Evans and Sherman 2010b) and HSRB recommendations, is likely to meet the appli-
1014 cable requirements of 40 CFR 26, subparts K and L.

1015 HSRB Detailed Recommendation and Rationale

1016
1017 The submitted documents assert that the revised study will be conducted in accordance
1018 with the ethical and regulatory standards of 40 CFR 26, Subparts K and L, as well as the re-
1019 quirements the US EPA's GLP Standards described at 40 CFR 160 (AHETF 2010c; Collier
1020 2010b). FIFRA §12(a)(2)(P) and the California State EPA Department of Pesticide Regulation's
1021 study monitoring requirements (California Code of Regulations Title 3, Section 6710) also apply.
1022 The protocol was reviewed and approved by an independent human subjects review committee,
1023 IIRB, Inc. of Plantation, FL prior to submission. Minutes of IIRB, Inc. meetings and a copy of
1024 IIRB, Inc. policies and procedures were provided. This IRB is fully accredited by AAHRPP and
1025 listed by OHRP (see details above).

- 1026
1027 1. Except as noted below, the Board concurred with the conclusions and factual observations of
1028 the ethical strengths and weaknesses of the revised study, as detailed in the EPA's Ethics Re-
1029 view (Evans and Sherman 2010b). The proposed study is likely to meet the applicable ethical
1030 requirements for research involving human participants, in accordance with the following cri-
1031 teria:
- 1032
1033 a. Acceptable risk-benefit ratio. Risks as noted in the study protocol are four-fold: 1) heat-
1034 related illness; 2) injury associated with scripted field activities; 3) allergic reaction to
1035 surfactants used for hand washing; and 4) psychological stress and/or breach of confiden-
1036 tiality for pregnancy test results. These risks are minimized appropriately and are justified

1037 by the potential societal benefits, particularly data on occupational exposure of agricul-
1038 tural workers to pesticides during mixing and loading activities.

- 1039
- 1040 • The greatest risk to participants is that of heat-related illness, given that the partici-
1041 pants will be required to wear two layers of clothing during the scenario activities.
1042 This risk is lessened but not eliminated by the application of appropriate stopping
1043 rules (including cessation of all monitoring activities when the ambient heat-index
1044 exceeds 105°F) and frequent monitoring of participants. Participants will be given
1045 frequent breaks, access to ample amounts of water or sports drinks, and educated
1046 about the dangers and symptoms of heat-related illness. Appropriate medical man-
1047 agement procedures are also in place.
- 1048
- 1049 • The surrogate materials consist of four common pesticides: acephate, dithiopyr,
1050 imidacloprid, and thiophanate-methyl. The participants will only be exposed to
1051 concentrations of the surrogate compound at accepted exposure thresholds.
- 1052
- 1053 • Participants will be selected from volunteers with experience handling these or
1054 similar compounds in WSP mixing and loading scenarios. Thus, all of the partici-
1055 pants will have extensive experience in using these or similar products, and thus
1056 will be unlikely to misuse them in a way that might increase their likelihood of be-
1057 ing accidentally exposed.
- 1058
- 1059 • Participants will be reminded about safe handling practices and procedures, about
1060 wearing appropriate PPE, and will be monitored for any accidental or unintended
1061 product exposure.
- 1062
- 1063 • Allergic reactions to the surfactants used in hand washing are usually mild and eas-
1064 ily treated with over-the-counter steroidal creams. The study will exclude partici-
1065 pants who have a history of severe skin reactions to such detergents.
- 1066
- 1067 • Minors and pregnant or lactating women are excluded from participation, with
1068 pregnancy either confirmed by over-the-counter pregnancy testing on the day of
1069 study or by opt-out. The potential stigma resulting from study exclusion due to
1070 pregnancy is also appropriately minimized.
- 1071

1072 Several members noted, however, that exposure to the surrogate chemicals is no longer
1073 listed as a potential risk to study participants in either the protocol or in the informed con-
1074 sent documents. Study volunteers, it was argued, are likely to handle these chemicals as
1075 part of their daily activities and the possibility of exposure is thus a risk of employment
1076 and not a risk of study participation. However, because of the nature of the study (includ-
1077 ing scripted handling of specific amounts of chemical), the Board felt that exposure to the
1078 surrogate chemicals was a potential risk of study participation and recommended that the
1079 sponsor explicitly list this risk in the protocol and informed consent documents.

1080

- 1081 b. Voluntary and informed consent of all participants
1082
1083 • There is the possibility that the participants in this study might represent particularly
1084 vulnerable populations, susceptible to coercion and undue influence. The study proto-
1085 col, however, includes several mechanisms designed to minimize coercive recruitment
1086 and enrollment.
1087
1088 • Monetary compensation is not so high as to unduly influence participants.
1089
1090 • Spanish translations of the informed consent documents, informational packets, and re-
1091 cruitment flyers were provided. Researchers will be working with local Spanish-
1092 speaking community members to ensure that the appropriate regional dialect of Spanish
1093 is used (AHETF 2010d).

1094
1095 c. Equitable selection of study participants

- 1096
1097 • The study is designed to recruit an appropriately diverse population of participants who
1098 represent skilled agricultural workers in the five study locations.
1099
1100 • Community representatives and advocates are appropriately involved in the recruitment
1101 and enrollment of study participants.

1102
1103 2. The Board recommended that the study protocol be modified to address the concerns noted in
1104 the EPA's Ethics Review (Evans and Sherman 2010b). In addition, the Board also raised the
1105 following concerns:

- 1106
1107 • The Board raised concerns that the revised water-soluble packaging protocol was reviewed
1108 by IIRB, Inc. using an expedited procedure. Future protocol revisions that involve major
1109 changes like substitution of surrogate compounds and/or change in study site should be re-
1110 viewed under full-board procedures and reflected properly in the IRB minutes.
1111
1112 • As noted above, the Board recommended that accidental exposure to the surrogate chemi-
1113 cals be listed in the protocol and that the informed consent form also list surrogate exposure
1114 as a potential risk of study participation.
1115
1116 • The protocol excludes participants who normally wear additional personal protective
1117 equipment (such as chemical-resistant clothing) that is not required by the chemical label
1118 and that might impact the objectives of the study. The Board recommended that this as-
1119 sessment be done in a non-directive way, so as not to encourage participants to wear less
1120 PPE than they would normally in order to participate in the study.
1121
1122 • Study participants will undergo hand washes prior to eating anything, which will reduce
1123 their risk of accidental ingestion of the surrogate compounds. As many of the adults in the
1124 U.S. still smoke, however, the Board recommended that hand washes also occur before any
1125 smoking break to further reduce their risk of accidental pesticide ingestion.
1126

- 1127
- 1128
- 1129
- 1130
- 1131
- 1132
- 1133
- 1134
- 1135
- 1136
- 1137
- 1138
- 1139
- 1140
- 1141
- 1142
- The informed consent document states that “you may refuse medical treatment *unless* you get sick from too much exposure to pesticides or from getting too hot, or *if we believe you are too sick to make a rational decision about getting medical treatment*” (Collier 2010b, emphasis added). It was unclear how this determination of rationality will be made, however. The protocol and informed consent document should be more explicit as to who will make this determination, and what criteria would be used.
 - The Board raised some concerns about how the Task Force plans to release individual exposure data to individual study participants who request this information. For example, the Board encouraged the sponsor to consider how this information might be provided to participants who do not speak English and/or are illiterate. The Board also recommended that the request for individual study results be included as a check box on the informed consent document. The HSRB will be establishing a small working group to develop some guidance for the Agency and sponsors regarding the release of individual exposure data to study participants.

1143 **REFERENCES**

- 1144
- 1145 Agricultural Handler Exposure Task Force (AHETF). 2010a. Supplemental 1 to the Backpack
1146 and Handgun Application of Liquid Sprays in Utilities Rights-of-Way Scenario Submission
1147 (AHE-400): SOPs Cited in AHE-400 ROW Submission. Undated and unpublished document
1148 prepared by the AHETF.
- 1149
- 1150 AHETF. 2010b. Supplemental 2 to the Backpack and Handgun Application of Liquid Sprays in
1151 Utilities Rights-of-Way Scenario Submission (AHE-400): Providing Individual Exposure
1152 Information to Subjects. Undated and unpublished document prepared by the AHETF.
- 1153
- 1154 AHETF. 2010c. Supplemental 1 to the Revised Water Soluble Packet Mixer/Loader Scenario
1155 Submission (AHE-120): SOPs Cited in AHE-120 ROW Submission. Undated and unpublished
1156 document prepared by the AHETF.
- 1157
- 1158 AHETF. 2010d. Supplemental 2 to the Revised Water Soluble Packet Mixer/Loader Scenario
1159 Submission (AHE-120): Providing Individual Exposure Information to Subjects. Undated and
1160 unpublished document prepared by the AHETF.
- 1161
- 1162 Carley, J.M. 2010. Ethics Review of Completed AEATF II Mop Scenario Worker Exposure
1163 Monitoring Study AEA-03. Dated October 4, 2010. Unpublished document prepared by the
1164 Office of Chemical Safety and Pollution Prevention, United States Environmental Protection
1165 Agency.
- 1166
- 1167 Carroll, S. 2010. Efficacy Test Protocol: Field Efficacy Test of PMD and Lemongrass Oil Based
1168 Repellent 'No Mas' Against Mosquitoes. Dated July 15, 2010. Unpublished document prepared
1169 by Carroll-Loye Biological Research.
- 1170
- 1171 Collier, C.H., for the Agricultural Handler Exposure Task Force (AHETF). 2010a. Backpack and
1172 Handgun Application of Liquid Sprays in Utilities Rights-of-Way Scenario Submission (AHE-
1173 400). Dated June 18, 2010. Unpublished document prepared by the AHETF.
- 1174
- 1175 Collier, C.H., for the Agricultural Handler Exposure Task Force (AHETF). 2010b. Revised Water
1176 Soluble Packet Mixer/Loader Scenario Submission (AHE-120). Dated August 19, 2010.
1177 Unpublished document prepared by the AHETF.
- 1178
- 1179 EPA Human Studies Review Board. 2008. April 9-10, 2008 Human Studies Review Board Meet-
1180 ing Report.
- 1181
- 1182 EPA Human Studies Review Board. 2009. June 24-25, 2009 Human Studies Review Board
1183 Meeting Report.
- 1184
- 1185 Evans, J., and K. Sherman. 2010a. Science and Ethics Review of AHE400: A New Scenario
1186 Design and Associated Protocol from the Agricultural Handler Exposure Task Force (AHETF)
1187 Describing Proposed Research to Measure Dermal and Inhalation Exposure to Applicators Who
1188 Use Backpack or Hand Gun Sprayers to Apply Pesticides in Utility Rights-of-Way. Dated

- 1189 September 30, 2010. Unpublished document prepared by the Office of Chemical Safety and
1190 Pollution Prevention, United States Environmental Protection Agency.
1191
- 1192 Evans, J., and K. Sherman. 2010b. Science and Ethics Review of Revised AHETF Scenario De-
1193 sign and Protocol AHE120 for Exposure Monitoring of Workers during Mixing and Loading of
1194 Pesticide Products in Water Soluble Packets in Five Regions of the United States (August 2010).
1195 Dated October 1, 2010. Unpublished document prepared by the Office of Chemical Safety and
1196 Pollution Prevention, United States Environmental Protection Agency.
1197
- 1198 Fuentes, C., and K. Sherman. 2010. Science and Ethics Review of Protocol for Human Study of
1199 Mosquito Repellent Performance: Proposed Carroll-Loye Field Efficacy Test of PMD and
1200 Lemongrass Oil-Based Repellent 'No Mas' Against Mosquitoes. Dated October 1, 2010.
1201 Unpublished document prepared by the Office of Chemical Safety and Pollution Prevention,
1202 United States Environmental Protection Agency.
1203
- 1204 Independent Institutional Review Board, Inc. (IIRB, Inc.). 2010. Roster and Procedures.
1205 Unpublished materials prepared by IIRB.
1206
- 1207 Johnson, D., for the Agricultural Handler Exposure Task Force (AHETF). 2010a. Supplemental 3
1208 to the Backpack and Handgun Application of Liquid Sprays in Utilities Rights-of-Way Scenario
1209 Submission (AHE-400): Explanation of AHETF Spanish Translation Project. Dated September
1210 30, 2010. Unpublished document prepared by the AHETF.
1211
- 1212 Johnson, D., for the Agricultural Handler Exposure Task Force (AHETF). 2010a. Supplemental 3
1213 to the Revised Water Soluble Packet Mixer/Loader Scenario Submission (AHE-120):
1214 Explanation of AHETF Spanish Translation Project. Dated September 30, 2010. Unpublished
1215 document prepared by the AHETF.
1216
- 1217 Leighton, T. 2010. Science Review of the AEATF II Mop Human Exposure Monitoring Study
1218 (AEA-03). MRID Numbers 48210201, 48231201, and 48231901 . Dated October 4, 2010.
1219 Unpublished document prepared by the Office of Chemical Safety and Pollution Prevention,
1220 United States Environmental Protection Agency.
1221
- 1222 Selim, S., and M.N. Taylor for the Antimicrobial Exposure Assessment Task Force II (AEATF
1223 II). 2010a. A Study for Measurement of Potential Dermal and Inhalation Exposure during
1224 Application of a Liquid Antimicrobial Pesticide Product Using Bucket and Mop Equipment for
1225 Cleaning Indoor Surfaces. Dated August 2, 2010. Unpublished document prepared by the
1226 AEATF II. MRID 48210201.
1227
- 1228 Selim, S., and M.N. Taylor for the Antimicrobial Exposure Assessment Task Force II (AEATF
1229 II). 2010b. Supplement 1 to A Study for Measurement of Potential Dermal and Inhalation
1230 Exposure during Application of a Liquid Antimicrobial Pesticide Product Using Bucket and Mop
1231 Equipment for Cleaning Indoor Surfaces. Dated September 15, 2010. Unpublished document
1232 prepared by the AEATF II. MRID 48231201.
1233
- 1234 Selim, S., and M.N. Taylor for the Antimicrobial Exposure Assessment Task Force II (AEATF

1235 II). 2010c. Supplement 2 to A Study for Measurement of Potential Dermal and Inhalation
1236 Exposure during Application of a Liquid Antimicrobial Pesticide Product Using Bucket and Mop
1237 Equipment for Cleaning Indoor Surfaces. Dated September 21, 2010. Unpublished document
1238 prepared by the AEATF II. MRID 48231901.

1239
1240 Appendix 1

1241
1242 [to be added at a later date]

DRAFT